Phathom Pharmaceuticals, Inc. Equity Repurchase (Common, Net)

Equity Repurchase (Common, Net) of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Equity Repurchase (Common, Net) growth rates and interactive chart.


Highlights and Quick Summary

  • Equity Repurchase (Common, Net) for the quarter ending September 29, 2021 was $1.27 Million (a 1116.35% increase compared to previous quarter)
  • Year-over-year quarterly Equity Repurchase (Common, Net) decreased by -98.59%
  • Annual Equity Repurchase (Common, Net) for 2020 was $89.5 Million (a -53.28% decrease from previous year)
  • Annual Equity Repurchase (Common, Net) for 2019 was $191 Million (a 9573500.0% increase from previous year)
  • Twelve month Equity Repurchase (Common, Net) ending September 29, 2021 was $91.2 Million (a -67.73% decrease compared to previous quarter)
  • Twelve month trailing Equity Repurchase (Common, Net) decreased by -67.52% year-over-year
Trailing Equity Repurchase (Common, Net) for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$91.2 Million $283 Million $281 Million $281 Million
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Equity Repurchase (Common, Net) of Phathom Pharmaceuticals, Inc.

Most recent Equity Repurchase (Common, Net)of PHAT including historical data for past 10 years.

Interactive Chart of Equity Repurchase (Common, Net) of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Equity Repurchase (Common, Net) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $1.27 $0.1 $0.41
2020 $89.46 $89.46
2019 $192.77 $-1.3 $191.47
2018 $0.0 $0.0

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.